<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37352070</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>25</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Clinical efficacy of belimumab in central nervous system demyelinating syndromes with systemic lupus erythematosus: A case series.</ArticleTitle><Pagination><StartPage>e34079</StartPage><MedlinePgn>e34079</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e34079</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000034079</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) is a complex autoimmune disease involving multiple systems. Central nervous system (CNS) demyelinating syndromes are one of the rare neurological manifestations of SLE, whose diagnosis, treatment, and prognosis are rarely reported. Belimumab, an anti-BAFF monoclonal antibody, has been approved by the FDA for the treatment of SLE. We aimed to assess the effects of belimumab on demyelinating syndromes in patients with SLE.</AbstractText><AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">Six patients with demyelination in SLE who were managed at Traditional Chinese and Western Medicine Hospital of Wuhan from March 2021 to March 2023, who received belimumab &#x2265; 5 times, were enrolled. Ten age- and sex-matched SLE patients with noutneuropsychiatric systemic lupus erythematosus (NPSLE) and normal controls were recruited to analyze potential biomarkers.</AbstractText><AbstractText Label="DIAGNOSES" NlmCategory="METHODS">All patients were diagnosed with SLE based on the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE classification criteria or the 2019 EULAR/ACR classification criteria. All SLE patients with CNS demyelinating syndromes were diagnosed by rheumatologists, neurologists, and radiologists.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">These patients were administered belimumab combined with standard treatment (glucocorticoids and/or antimalarials and/or immunosuppressants [cyclophosphamide, mycophenolate, methotrexate, etc.]).</AbstractText><AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Six patients were included in the study (100% female, mean [range] age at first demyelinating episode 42.8 [24-66] years). The most common extra-CNS features in these patients were rash, arthritis, alopecia, leukopenia, and hypocomplementemia. After Belimumab treatment, 3 of 6 (50%) patients achieved complete remission with decreased prednisone, 2 improvements, and 1 relapsed with uterine surgery. Compared with the baseline, 3.5 months post belimumab treatment, the disease activity score SLEDAI (21.5-5.5, P &lt; .001), C3 and C4 increased, and extra-CNS symptoms improved rapidly. Moreover, The expression of lupus susceptibility gene PBX1 in CD19+ B cells was lowest in demyelinating syndromes with lupus patients compared with healthy volunteers and lupus patients without demyelination, and its relative expression negatively correlated with SLE disease activity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Belimumab could be an effective and safe option for the treatment of SLE demyelination. In addition, PBX1 might be a potential biomarker for the clinical diagnosis of lupus in patients with demyelinating syndrome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Qiuyu</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Chao</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Qibin</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Huiqin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0008-0434-4528</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="Y">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37352070</ArticleId><ArticleId IdType="pmc">PMC10289687</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000034079</ArticleId><ArticleId IdType="pii">00005792-202306230-00051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393:2332&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol. 2019;15:137&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023338</ArticleId><ArticleId IdType="pubmed">30659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri&#xf3;n-Barber&#xe0; I, Salman-Monte TC, V&#xed;lchez-Oya F, et al. . Neuropsychiatric involvement in systemic lupus erythematosus: a review. Autoimmun Rev. 2021;20:102780.</Citation><ArticleIdList><ArticleId IdType="pubmed">33609799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo-Piraquive V, Nieto-Aristiz&#xe1;bal I, Ca&#xf1;as CA, et al. . Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14:1043&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30338717</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiserman B, da Silva LF, Keiserman MW, et al. . Lupoid sclerosis. Rheumatol Int. 2010;30:431&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19826821</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Chessa E, Peltz MT, et al. . Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16:244&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28159705</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ckel T, Basta F, Weinmann-Menke J, et al. . B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2021;20:102736.</Citation><ArticleIdList><ArticleId IdType="pubmed">33333233</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair HA, Duggan ST. Belimumab: A Review in systemic lupus erythematosus. Drugs. 2018;78:355&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">29396833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Zhao CS, Yan CL, et al. . Efficacy of Belimumab for refractory systemic lupus erythematosus (SLE) involving the central nervous system. Eur J Intern Med. 2021;92:117&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">34226115</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2:CD010668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095005</ArticleId><ArticleId IdType="pubmed">33631841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . 2019 european league against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S, Zhang J, Han X, et al. . The transcriptional factor Pbx1 adjusts peripheral B cell homeostasis to constrain lupus autoimmunity [published online ahead of print, March 2, 2023]. Arthritis Rheumatol. doi: 10.1002/art.42487.</Citation><ArticleIdList><ArticleId IdType="pubmed">36862399</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro Checa C, Cohen D, Bollen EL, et al. . Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract Res Clin Rheumatol. 2013;27:405&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24238696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen T, New D, Reeve R, et al. . Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: case report and review of the literature. NDT Plus. 2009;2:466&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4421313</ArticleId><ArticleId IdType="pubmed">25949381</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6:358&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">20458332</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulos D, Kitsos D, Papathanasiou M, et al. . Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. Rheumatology (Oxford). 2021;60:4166&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33404657</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuda CM, Li S, Liang S, et al. . Pre-B cell leukemia homeobox 1 is associated with lupus susceptibility in mice and humans. J Immunol. 2012;188:604&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253202</ArticleId><ArticleId IdType="pubmed">22180614</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuda CM, Zeumer L, Sobel ES, et al. . Murine lupus susceptibility locus Sle1a requires the expression of two sub-loci to induce inflammatory T cells. Genes Immun. 2010;11:542&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958247</ArticleId><ArticleId IdType="pubmed">20445563</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>